Status:
UNKNOWN
Liver Cirrhosis Diagnosis Prioritizing Algorithm Based on Electronic Health Records.
Lead Sponsor:
HaEmek Medical Center, Israel
Collaborating Sponsors:
Weizmann Institute of Science
Conditions:
NAFLD - Nonalcoholic Fatty Liver Disease
Fibrosis, Liver
Eligibility:
All Genders
40-75 years
Brief Summary
The investigators use machine learning capabilities on massive electronic health records for the purpose of developing a model that prioritizes individuals at high risk of progressing to liver cirrhos...
Detailed Description
In this study the investigators harness modern capabilities of machine learning in the field of hepatology for developing a model that can identify prioritize individuals at high risk of progressing t...
Eligibility Criteria
Inclusion
- Subjects with electronic health records from Clalit Healthcare's North district
- Ages 40-75
Exclusion
- No lab test results for Hemoglobin, platelet, or white blood cell count.
- Known Viral Hepatitis (HBV, HCV, HDV).
- Known liver cirrhosis.
- Known lipidoses.
- Known alpha-1-antitrypsin deficiency.
- Known hemochromatosis.
- Known disorders of copper metabolism.
- Known Budd-Chiari syndrome.
- Known alcoholic fatty liver.
- Known diagnosis for alcohol abuse.
- Known Autoimmune Hepatitis.
- Known biliary cirrhosis.
- Known cholangitis.
- Undergone liver replacement by transplant.
- Right Heart Failure.
Key Trial Info
Start Date :
March 15 2022
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
December 1 2023
Estimated Enrollment :
120 Patients enrolled
Trial Details
Trial ID
NCT05218538
Start Date
March 15 2022
End Date
December 1 2023
Last Update
March 31 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Haemek medical center
Afula, North, Israel, 1834111